| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for ART Advanced Research Technologies, Inc. > News item |
ART starts clinical trials of SoftScan system at University of California-San Diego
By Elaine Rigoli
Tampa, Fla., March 29 - ART Advanced Research Technologies, Inc. is undertaking clinical trials at the Moores Cancer Center, University of California, San Diego, as part of its North American pivotal study for the SoftScan optical breast imaging system.
"We are delighted to be associated with this prestigious institution. This site will give us access to an important pool of patients and contribute to the success of pivotal trials now underway across Canada and the U.S.," said Micheline Bouchard, ART president and chief executive officer, in a news release.
Through participation in this study, the Moores Cancer Center is joining Cedars Breast Clinic of the McGill University Health Centre, the Centre Hospitalier de l'Université de Montréal, the Central Alberta Medical Imaging Services, the UHN Princess Margaret Hospital and the Massachusetts General Hospital, in bringing the SoftScan device to market.
ART said this study represents the final stage prior to commercializing SoftScan, a noninvasive optical breast imaging system designed to improve the diagnosis and treatment of breast cancer.
ART said it will present results of the study in its submission to Health Canada and the Food and Drug Administration to support its pre-market approval application for SoftScan.
SoftScan has been designed first as a complementary diagnostic tool to mammography, to be ultimately used for the detection and treatment monitoring of breast cancer, the release said.
ART, based in Montreal, Quebec, develops products in medical imaging, medical diagnostics, disease research and drug discovery.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.